- Fiji Kava (FIJ) has seen its shares soar more than 43 per cent after signing a licence agreement with BioCeuticals, which is owned by ASX 200-lister Blackmores (BKL)
- BioCeuticals will licence the use of Fiji Kava’s high-quality noble kava extract for its BioCeuticals Clinical AnxioCalm product
- BioCeuticals is renowned for developing high-quality integrative medicines to healthcare practitioners across Australia, New Zealand and the U.S
- Fiji Kava Founder and CEO Zane Yoshida says the agreement is “another strong endorsement … of the quality and uniqueness of our Fijian noble kava”
- Company shares are up 43.7 per cent and trading for 12.5 cents
Fiji Kava (FIJ) has seen its shares soar more than 43 per cent after signing a licence agreement with Blackmores’ (BKL) subsidiary, BioCeuticals.
The non-exclusive agreement will see BioCeuticals licence the use of Fiji Kava’s noble kava extract for its BioCeuticals Clinical AnxioCalm product. This product is a unique blend of herbs which support the relief of mild anxiety, tension and stress, and is formulated to support the nervous system.
“This is another milestone for the company that will not only increase the availability of our noble kava in Australia and New Zealand, but is another strong endorsement by a leading healthcare provider of the quality and uniqueness of our Fijian noble kava,” Fiji Kava Founder and CEO Zane Yoshida said.
BioCeuticals is a well-known manufacturer and supplier of high-quality integrative medicines to healthcare practitioners across Australia, New Zealand and the U.S. Its parent organisation, Blackmores, is an ASX 200-listed company and a leading practitioner brand in Australia.
The integrated AnxioCalm products will be co-branded with Fiji’s ‘Authentic Fiji Kava’ trademark, which will be clearly displayed on each product’s packaging. AnxioCalm will be available through BioCeuticals’ network of qualified healthcare practitioners in Australia and New Zealand.
“In particular, we are proud to support BioCeuticals with our water extracted Noble Fiji Kava, as allowed by the TGA in Australia. We are able to deliver this to BioCeuticals and our other partners through our vertically integrated supply chain, guaranteeing a sustainable and 100 per cent traceable supply of unadulterated Noble Fiji Kava,” Zane stated.
Noble kava is a safe and natural product that is found in Fiji and commonly used for medicinal and relaxation purposes.
This agreement continues the momentum Fiji Kava has recently experienced including the launch of its noble kava capsule range in Coles Supermarkets and the recent partnership with the Pacific Horticultural and Agricultural Market Access (PHAMA) Plus Program to strengthen kava export opportunities.
Company shares are up 43.7 per cent and trading for 12.5 cents each at 10:27 am AEST.